Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Sickle Cell Disease Treatment Market, by Treatment
1.4.2 Global Sickle Cell Disease Treatment Market, by End-Use
1.4.3 Global Sickle Cell Disease Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Global Sickle Cell Disease Treatment Market by Treatment
5.1 Global Blood Transfusion Market by Region
5.2 Global Pharmacotherapy Market by Region
5.3 Global Bone Marrow Transplant Market by Region
Chapter 6. Global Sickle Cell Disease Treatment Market by End-use
6.1 Global Hospitals Market by Region
6.2 Global Specialty Clinics Market by Region
6.3 Global Others Market by Region
Chapter 7. Global Sickle Cell Disease Treatment Market by Region
7.1 North America Sickle Cell Disease Treatment Market
7.1.1 North America Sickle Cell Disease Treatment Market by Treatment
7.1.1.1 North America Blood Transfusion Market by Country
7.1.1.2 North America Pharmacotherapy Market by Country
7.1.1.3 North America Bone Marrow Transplant Market by Country
7.1.2 North America Sickle Cell Disease Treatment Market by End-use
7.1.2.1 North America Hospitals Market by Country
7.1.2.2 North America Specialty Clinics Market by Country
7.1.2.3 North America Others Market by Country
7.1.3 North America Sickle Cell Disease Treatment Market by Country
7.1.3.1 US Sickle Cell Disease Treatment Market
7.1.3.1.1 US Sickle Cell Disease Treatment Market by Treatment
7.1.3.1.2 US Sickle Cell Disease Treatment Market by End-use
7.1.3.2 Canada Sickle Cell Disease Treatment Market
7.1.3.2.1 Canada Sickle Cell Disease Treatment Market by Treatment
7.1.3.2.2 Canada Sickle Cell Disease Treatment Market by End-use
7.1.3.3 Mexico Sickle Cell Disease Treatment Market
7.1.3.3.1 Mexico Sickle Cell Disease Treatment Market by Treatment
7.1.3.3.2 Mexico Sickle Cell Disease Treatment Market by End-use
7.1.3.4 Rest of North America Sickle Cell Disease Treatment Market
7.1.3.4.1 Rest of North America Sickle Cell Disease Treatment Market by Treatment
7.1.3.4.2 Rest of North America Sickle Cell Disease Treatment Market by End-use
7.2 Europe Sickle Cell Disease Treatment Market
7.2.1 Europe Sickle Cell Disease Treatment Market by Treatment
7.2.1.1 Europe Blood Transfusion Market by Country
7.2.1.2 Europe Pharmacotherapy Market by Country
7.2.1.3 Europe Bone Marrow Transplant Market by Country
7.2.2 Europe Sickle Cell Disease Treatment Market by End-use
7.2.2.1 Europe Hospitals Market by Country
7.2.2.2 Europe Specialty Clinics Market by Country
7.2.2.3 Europe Others Market by Country
7.2.3 Europe Sickle Cell Disease Treatment Market by Country
7.2.3.1 Germany Sickle Cell Disease Treatment Market
7.2.3.1.1 Germany Sickle Cell Disease Treatment Market by Treatment
7.2.3.1.2 Germany Sickle Cell Disease Treatment Market by End-use
7.2.3.2 UK Sickle Cell Disease Treatment Market
7.2.3.2.1 UK Sickle Cell Disease Treatment Market by Treatment
7.2.3.2.2 UK Sickle Cell Disease Treatment Market by End-use
7.2.3.3 France Sickle Cell Disease Treatment Market
7.2.3.3.1 France Sickle Cell Disease Treatment Market by Treatment
7.2.3.3.2 France Sickle Cell Disease Treatment Market by End-use
7.2.3.4 Russia Sickle Cell Disease Treatment Market
7.2.3.4.1 Russia Sickle Cell Disease Treatment Market by Treatment
7.2.3.4.2 Russia Sickle Cell Disease Treatment Market by End-use
7.2.3.5 Spain Sickle Cell Disease Treatment Market
7.2.3.5.1 Spain Sickle Cell Disease Treatment Market by Treatment
7.2.3.5.2 Spain Sickle Cell Disease Treatment Market by End-use
7.2.3.6 Italy Sickle Cell Disease Treatment Market
7.2.3.6.1 Italy Sickle Cell Disease Treatment Market by Treatment
7.2.3.6.2 Italy Sickle Cell Disease Treatment Market by End-use
7.2.3.7 Rest of Europe Sickle Cell Disease Treatment Market
7.2.3.7.1 Rest of Europe Sickle Cell Disease Treatment Market by Treatment
7.2.3.7.2 Rest of Europe Sickle Cell Disease Treatment Market by End-use
7.3 Asia Pacific Sickle Cell Disease Treatment Market
7.3.1 Asia Pacific Sickle Cell Disease Treatment Market by Treatment
7.3.1.1 Asia Pacific Blood Transfusion Market by Country
7.3.1.2 Asia Pacific Pharmacotherapy Market by Country
7.3.1.3 Asia Pacific Bone Marrow Transplant Market by Country
7.3.2 Asia Pacific Sickle Cell Disease Treatment Market by End-use
7.3.2.1 Asia Pacific Hospitals Market by Country
7.3.2.2 Asia Pacific Specialty Clinics Market by Country
7.3.2.3 Asia Pacific Others Market by Country
7.3.3 Asia Pacific Sickle Cell Disease Treatment Market by Country
7.3.3.1 China Sickle Cell Disease Treatment Market
7.3.3.1.1 China Sickle Cell Disease Treatment Market by Treatment
7.3.3.1.2 China Sickle Cell Disease Treatment Market by End-use
7.3.3.2 Japan Sickle Cell Disease Treatment Market
7.3.3.2.1 Japan Sickle Cell Disease Treatment Market by Treatment
7.3.3.2.2 Japan Sickle Cell Disease Treatment Market by End-use
7.3.3.3 India Sickle Cell Disease Treatment Market
7.3.3.3.1 India Sickle Cell Disease Treatment Market by Treatment
7.3.3.3.2 India Sickle Cell Disease Treatment Market by End-use
7.3.3.4 South Korea Sickle Cell Disease Treatment Market
7.3.3.4.1 South Korea Sickle Cell Disease Treatment Market by Treatment
7.3.3.4.2 South Korea Sickle Cell Disease Treatment Market by End-use
7.3.3.5 Singapore Sickle Cell Disease Treatment Market
7.3.3.5.1 Singapore Sickle Cell Disease Treatment Market by Treatment
7.3.3.5.2 Singapore Sickle Cell Disease Treatment Market by End-use
7.3.3.6 Malaysia Sickle Cell Disease Treatment Market
7.3.3.6.1 Malaysia Sickle Cell Disease Treatment Market by Treatment
7.3.3.6.2 Malaysia Sickle Cell Disease Treatment Market by End-use
7.3.3.7 Rest of Asia Pacific Sickle Cell Disease Treatment Market
7.3.3.7.1 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment
7.3.3.7.2 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use
7.4 LAMEA Sickle Cell Disease Treatment Market
7.4.1 LAMEA Sickle Cell Disease Treatment Market by Treatment
7.4.1.1 LAMEA Blood Transfusion Market by Country
7.4.1.2 LAMEA Pharmacotherapy Market by Country
7.4.1.3 LAMEA Bone Marrow Transplant Market by Country
7.4.2 LAMEA Sickle Cell Disease Treatment Market by End-use
7.4.2.1 LAMEA Hospitals Market by Country
7.4.2.2 LAMEA Specialty Clinics Market by Country
7.4.2.3 LAMEA Others Market by Country
7.4.3 LAMEA Sickle Cell Disease Treatment Market by Country
7.4.3.1 Brazil Sickle Cell Disease Treatment Market
7.4.3.1.1 Brazil Sickle Cell Disease Treatment Market by Treatment
7.4.3.1.2 Brazil Sickle Cell Disease Treatment Market by End-use
7.4.3.2 Argentina Sickle Cell Disease Treatment Market
7.4.3.2.1 Argentina Sickle Cell Disease Treatment Market by Treatment
7.4.3.2.2 Argentina Sickle Cell Disease Treatment Market by End-use
7.4.3.3 UAE Sickle Cell Disease Treatment Market
7.4.3.3.1 UAE Sickle Cell Disease Treatment Market by Treatment
7.4.3.3.2 UAE Sickle Cell Disease Treatment Market by End-use
7.4.3.4 Saudi Arabia Sickle Cell Disease Treatment Market
7.4.3.4.1 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment
7.4.3.4.2 Saudi Arabia Sickle Cell Disease Treatment Market by End-use
7.4.3.5 South Africa Sickle Cell Disease Treatment Market
7.4.3.5.1 South Africa Sickle Cell Disease Treatment Market by Treatment
7.4.3.5.2 South Africa Sickle Cell Disease Treatment Market by End-use
7.4.3.6 Nigeria Sickle Cell Disease Treatment Market
7.4.3.6.1 Nigeria Sickle Cell Disease Treatment Market by Treatment
7.4.3.6.2 Nigeria Sickle Cell Disease Treatment Market by End-use
7.4.3.7 Rest of LAMEA Sickle Cell Disease Treatment Market
7.4.3.7.1 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment
7.4.3.7.2 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives for Sickle Cell Disease Treatment Market
Unique Offerings 
